GRN-529
GRN-529 is a research drug that was developed by Wyeth as a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5). A study conducted by Pfizer found that GRN-529 reduced repetitive behaviors without sedation and partially increased sociability in mouse models of autism. Another study conducted by Pfizer found a therapeutically relevant effect in animal models of depression. It is theorized to work by reducing glutamate receptor hyperactivity.
Wikipage redirect
primaryTopic
GRN-529
GRN-529 is a research drug that was developed by Wyeth as a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5). A study conducted by Pfizer found that GRN-529 reduced repetitive behaviors without sedation and partially increased sociability in mouse models of autism. Another study conducted by Pfizer found a therapeutically relevant effect in animal models of depression. It is theorized to work by reducing glutamate receptor hyperactivity.
has abstract
GRN-529 is a research drug tha ...... tamate receptor hyperactivity.
@en
CAS number
1253291-12-1
IUPAC name
(4-(Difluoromethoxy)-3-(pyridi ...... 4-b]pyridin-6(7H)-yl)methanone
@en
thumbnail
Wikipage page ID
35,784,368
Wikipage revision ID
713,205,242
ChemSpiderID
27,471,591
IUPHAR ligand
molecular weight
smiles
O=CC3=CC=CC=C3
StdInChIKey
JITMSIRHBAVREW-UHFFFAOYSA-N
hypernym
comment
GRN-529 is a research drug tha ...... tamate receptor hyperactivity.
@en
label
GRN-529
@en
